Microglial activation by components of gram-positive and -negative bacteria: distinct and common routes to the induction of ion channels and cytokines.
Gram-positive Streptococcus pneumoniae is the major pathogen causing lethal meningitis in adults. We used pneumococcal cell walls (PCW) to investigate microglial consequences of a bacterial challenge and to determine the role of serum in the activation process. PCW caused the characteristic induction of an outwardly rectifying K+ channel (IK+(OR)), together with a concomitant suppression of the constitutively expressed inward rectifier K+ current, and evoked the release of tumor necrosis factor-alpha (TNF alpha), interleukin-6 (IL-6), IL-12, KC, macrophage inflammatory protein (MIP) 1alpha and MIP-2. Serum presence strongly facilitated the PCW effects, similarly as observed for lipopolysaccharide (LPS) from gram-negative Escherichia coli. The inflammatory cytokine, interferon-gamma (IFNgamma) induced the same electrophysiological changes, but independent of serum. Recombinant LPS binding protein (LBP) could partially replace serum activity in LPS stimulations. In contrast, neither LBP nor an antibody-mediated blockade of the LPS receptor, CD14 had significant influences on PCW-inducible changes. Cell surface interactions and cofactor involvement in microglial activation by gram-positive bacteria are thus distinct from the mechanisms employed by LPS. Moreover, tyrphostin AG126, a protein kinase inhibitor that prevents activation of the mitogen-activated protein kinase, p42MAPK (ERK2), potently blocked the PCW-stimulated cytokine release while having only a limited effect on LPS-inducible cytokines. In contrast, AG126 did not influence IK+(OR) inductions. This indicates that PCW recruits more than 1 intracellular signaling pathway to trigger the various responses and that different bacterial agents signal through both common and individual routes during microglial activation.
Prinz
M
M
Department of Cellular Neurosciences, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Kann
O
O
Draheim
H J
HJ
Schumann
R R
RR
Kettenmann
H
H
Weber
J R
JR
Hanisch
U K
UK
D000209:Acute-Phase Proteins; D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism; D001790:Blood Physiological Phenomena; D002352:Carrier Proteins / Q000494:pharmacology; D002473:Cell Wall / Q000502:physiology; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D004357:Drug Synergism; D004622:Embryo, Mammalian / Q000166:cytology / Q000378:metabolism; D006090:Gram-Negative Bacteria / Q000502:physiology*; D006094:Gram-Positive Bacteria / Q000502:physiology*; D007371:Interferon-gamma / Q000494:pharmacology; D007473:Ion Channels / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008562:Membrane Glycoproteins; D051379:Mice; D017628:Microglia / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology* / Q000502:physiology*; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism; D011494:Protein Kinases / Q000502:physiology; D011994:Recombinant Proteins; D013296:Streptococcus pneumoniae / Q000502:physiology; D000099231:Lipopolysaccharide-Binding Protein
D000209:Acute-Phase Proteins; D002352:Carrier Proteins; D016207:Cytokines; D007371:Interferon-gamma; D007473:Ion Channels; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D015221:Potassium Channels; D011494:Protein Kinases; D011994:Recombinant Proteins; D000099231:Lipopolysaccharide-Binding Protein